Xeris Biopharma Holdings, Inc. (LON:0A8E)

Xeris Biopharma Holdings Statistics

Total Valuation

LON:0A8E has a market cap or net worth of GBP 783.03 million. The enterprise value is 893.59 million.

Market Cap	783.03M
Enterprise Value	893.59M

Important Dates

The last earnings date was Monday, March 2, 2026.

Earnings Date	Mar 2, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	172.43M
Shares Outstanding	n/a
Shares Change (YoY)	+17.69%
Shares Change (QoQ)	+1.38%
Owned by Insiders (%)	4.99%
Owned by Institutions (%)	58.94%
Float	163.83M

Valuation Ratios

The trailing PE ratio is 1,902.30 and the forward PE ratio is 47.56.

PE Ratio	1,902.30
Forward PE	47.56
PS Ratio	3.61
PB Ratio	76.99
P/TBV Ratio	n/a
P/FCF Ratio	37.73
P/OCF Ratio	36.82
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 26.40, with an EV/FCF ratio of 43.06.

EV / Earnings	2,170.91
EV / Sales	4.07
EV / EBITDA	26.40
EV / EBIT	47.74
EV / FCF	43.06

Financial Position

The company has a current ratio of 2.19, with a Debt / Equity ratio of 18.85.

Current Ratio	2.19
Quick Ratio	1.48
Debt / Equity	18.85
Debt / EBITDA	5.73
Debt / FCF	9.24
Interest Coverage	0.86

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	4.40%
Return on Invested Capital (ROIC)	6.06%
Return on Capital Employed (ROCE)	9.09%
Weighted Average Cost of Capital (WACC)	9.29%
Revenue Per Employee	498,485
Profits Per Employee	946
Employee Count	394
Asset Turnover	0.83
Inventory Turnover	0.73

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +67.49% in the last 52 weeks. The beta is 0.93, so LON:0A8E's price volatility has been similar to the market average.

Beta (5Y)	0.93
52-Week Price Change	+67.49%
50-Day Moving Average	7.12
200-Day Moving Average	6.82
Relative Strength Index (RSI)	35.24
Average Volume (20 Days)	3,359

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	8.15

Income Statement

In the last 12 months, LON:0A8E had revenue of GBP 216.84 million and earned 411,622 in profits. Earnings per share was 0.00.

Revenue	216.84M
Gross Profit	185.21M
Operating Income	18.50M
Pretax Income	411,622
Net Income	411,622
EBITDA	27.53M
EBIT	18.50M
Earnings Per Share (EPS)	0.00

Balance Sheet

The company has 82.50 million in cash and 191.77 million in debt, with a net cash position of -109.26 million.

Cash & Cash Equivalents	82.50M
Total Debt	191.77M
Net Cash	-109.26M
Net Cash Per Share	n/a
Equity (Book Value)	10.17M
Book Value Per Share	0.06
Working Capital	97.14M

Cash Flow

In the last 12 months, operating cash flow was 21.27 million and capital expenditures -517,128, giving a free cash flow of 20.75 million.

Operating Cash Flow	21.27M
Capital Expenditures	-517,128
Free Cash Flow	20.75M
FCF Per Share	n/a

Margins

Gross margin is 85.41%, with operating and profit margins of 8.53% and 0.19%.

Gross Margin	85.41%
Operating Margin	8.53%
Pretax Margin	0.19%
Profit Margin	0.19%
EBITDA Margin	12.70%
EBIT Margin	8.53%
FCF Margin	9.57%

Dividends & Yields

LON:0A8E does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-17.69%
Shareholder Yield	-17.69%
Earnings Yield	0.05%
FCF Yield	2.65%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0A8E has an Altman Z-Score of 0.44 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.44
Piotroski F-Score	7